{
    "clinical_study": {
        "@rank": "6665", 
        "arm_group": [
            {
                "arm_group_label": "Abametapir Lotion 0.74% w/w", 
                "arm_group_type": "Active Comparator", 
                "description": "Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver."
            }, 
            {
                "arm_group_label": "Vehicle Lotion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the efficacy, safety and tolerability of a single\n      application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to\n      the scalp and hair for 10 minutes at home."
        }, 
        "brief_title": "Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Head Lice Infestation", 
        "condition_browse": {
            "mesh_term": [
                "Lice Infestations", 
                "Parasitic Diseases", 
                "Mite Infestations"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, aged six months of age or older.\n\n          2. Is in good general health based on medical history.\n\n          3. Has active head lice infestation at Screening as determined by a trained evaluator\n             with the exception of the male head of household who may self-assess as being\n             lice-free.  Active head lice infestation is defined as at least three live lice for\n             the index subject and at least one live louse for the other household members.\n\n          4. The subject and/or their caregiver is physically able and willing to apply the\n             Investigational Product at home.\n\n          5. Belongs to a household with an eligible index subject with active head lice\n             infestation.\n\n          6. Agrees to an examination for head lice and to all visits and procedures throughout\n             the study.\n\n          7. Has signed an informed consent and/or assent form.\n\n        Exclusion Criteria:\n\n          1. Had treatment (over-the-counter ), home remedy or prescription medication) for head\n             lice within 14 days prior to Day 0.\n\n          2. Intends to use any other form of lice treatment from Day 0 through the Day 14 visit,\n             unless provided as rescue therapy to this Protocol.\n\n          3. Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as\n             rescue therapy to this Protocol.\n\n          4. Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling\n             from Day 0 through the Day 14 visit.\n\n          5. Has a household member(s) who is infested with lice but is not willing or not\n             eligible for enrollment.\n\n          6. Has a condition that, in the opinion of the Investigator, may increase the risk to\n             the subject and/or the interpretation of the data.\n\n          7. Has visible skin/scalp condition(s) that are not attributable to head lice\n             infestation, such as an erythema score that is >2, blisters, vesicles which, in the\n             opinion of the investigative personnel or Sponsor, will interfere with safety and/or\n             efficacy evaluations.\n\n          8. Has eczema or atopic dermatitis of skin/scalp.\n\n          9. Has had a prior reaction to Nix\u00ae or products containing permethrin.\n\n         10. Receiving systemic or topical medication, which in the opinion of the Investigator,\n             may compromise the integrity of the safety and/or efficacy assessments.\n\n         11. Has received an investigational agent within 30 days prior to Day 0.\n\n         12. Does not have a known household affiliation with the household members (i.e., does\n             not stay in one household consistently, or sleeps at one place for several nights and\n             then at another place or location)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "318", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060903", 
            "org_study_id": "Ha03-001"
        }, 
        "intervention": {
            "arm_group_label": "Abametapir Lotion 0.74% w/w", 
            "intervention_name": "Abametapir Lotion 0.74% w/w", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Head Lice", 
            "Hatchtech"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "universalbiopharmainc@yahoo.com", 
                    "last_name": "David Cardona"
                }, 
                "facility": {
                    "address": {
                        "city": "Dinuba", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93618"
                    }, 
                    "name": "Universal Biopharma Reserach INC"
                }, 
                "investigator": {
                    "last_name": "David Cardona", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gina@licesolutions.org", 
                    "last_name": "Jeffry Seiler"
                }, 
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33407"
                    }, 
                    "name": "LSRN Reserach"
                }, 
                "investigator": {
                    "last_name": "Jeffry Seiler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation", 
        "overall_contact": {
            "email": "vlanoce@accelovance.com", 
            "last_name": "Vita Lanoce", 
            "phone": "772 2141745"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The outcome is measured by lice evaluations from baseline through follow up visits.", 
            "measure": "Proportion of index subjects who are lice-free at all follow-up visits through to the Day 14 visit.", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060903"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hatchtech Pty Ltd", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Accelovance Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "INC Research", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hatchtech Pty Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}